Authors
Latest:
How AI is Revamping the Product LaunchNew technology is allowing teams to analyze data at faster rates and make decisions much sooner than they previously could.
Latest:
Strategic Planning in the Rebate Economy: What Pharma Must Do Now35 years of manufacturer rebates by any other name.
Latest:
Are We Forgetting to Develop Vaccines for Diseases other than COVID?It's time to apply the same COVID-19 urgency to other devastating diseases, such as Alzheimer’s, write Andrea Pfeifer and William Mobley.
Latest:
New Product Planning: The Function's Evolution in PharmaWith an organization's future commercial success under its remit, the NPP function has rapidly progressed to a prominent role in the biopharma industry—but evidence-generation strategies must evolve with an eye toward emerging trends and technologies.
Latest:
Protecting Human Health with Organ-on-a-Chip TechnologyOrgan-on-a-Chip technology has been proven to predict DILI with a higher rate of confidence than traditional in vitro methods and animals. Start protecting human health today.
Latest:
Technology the equalizer for Patient Support ProgramsDelivering on the mission of personalized patient support
Latest:
Anticipating Digital Transformation of the Drug Development WorkforceThe drug development sector is embracing technologies and digital methods that were previously not as widely used due to the COVID-19 global health crisis.
Latest:
Market Segmentation with Novel Machine LearningMerging strengths of traditional behavioral and attitudinal research, capability enables pharmaceutical field teams to prioritize resources, targets, and outreach strategies.
Latest:
Four for 2024: Predictions for the Future of Pharmacy TechnologyIndustry stakeholders must come together to make meaningful changes to reimbursement and establish comprehensive policies that support essential healthcare providers.
Latest:
Success Factors for Orphan Drug DevelopmentWhen approached correctly, drug development in the rare disease space can be quite successful – especially when powerhouses across the industry join forces and leverage the power of data to help drive potential treatment options.
Latest:
The Role and Recruitment of the Chief Patient OfficerNew C-Suite position emerges for more emphasis on patient centricity.
Latest:
Driving the Speed of Adoption with Decentralized Clinical TrialsBiopharma companies and contract research organizations (CROs) adopted decentralized or digital clinical trials (DCTs) to reduce contact, improve the patient experience and keep studies on track during the pandemic. It’s already clear that the virtual approach of DCTs are benefiting life science organizations. From improvements in clinical trial operations such as enhanced patient engagement and site experience to cost savings and better data integration, the clinical trial dynamic has shifted and supports DCTs as a legitimate way to execute studies.
Latest:
Engaging Patients: Why Pharma’s Direct-to-Patient Approach Should Be ApplaudedPhysicians remain central even as DTP programs are implemented.
Latest:
Osteoarthritis: Is a Cure on the Launch Pad?Common advice for OA sufferers is joint replacement, but other options are on the horizon.
Latest:
Strategic Realignment for a Better Future 1In adjusting to the long-term aftershocks from the coronavirus pandemic, pharma companies will need to focus on change in three core areas.
Latest:
Medical Affairs Role in Shaping StrategyWhat the Changing Healthcare Landscape Demands of Future MA Professionals?
Latest:
Eyeing Efficiency for AllPaige Bingham has focused her career on improving clinical research operations and logistics, and not just ways to ease the burden for investigators and teams running the trials—but also for the patients involved in them.
Latest:
Scientific Storytelling for Medical AffairsStorytelling can be used very effectively to communicate with medical professionals without compromising the science, writes Stacey Rivkin.
Latest:
Biopharma’s Role in Transforming the Oncology MarketplaceBiopharma must step up amidst growing oncology market.
Latest:
Unlock Real World Evidence with Pragmatic Data Governance and Quality PracticesHow companies are leveraging Real Word Evidence to evaluate therapies under real world conditions in a broader population at a lower cost than using Randomized Clinical Trials.
Latest:
Beyond Awareness: Modeling Shared Decision-Making in Patient CommunicationsWhen patients struggle to see a positive path forward, modeling a constructive journey can give them the confidence they need.
Latest:
Recent Federal Circuit Developments in Patent LicensingUnderstanding of recent legal developments can help companies avoid infringement.
Latest:
Digital Tools are Key to Advancing the Tech Revolution in PharmaTheir integration across enterprise remains pivotal driver for success.
Latest:
Impact, Access, and Scale: The Potential of India’s Pharma MarketCountry is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.
Latest:
Strategic Realignment for a Better Future 1In adjusting to the long-term aftershocks from the coronavirus pandemic, pharma companies will need to focus on change in three core areas.
Latest:
The Future of Personalized Medicine Hinges on Pharma Executives Revolutionizing Business ModelsThe era of big pharma as product-first companies must end, as services become the larger priority.
Latest:
The Growth of International Arbitration in the Life Sciences SectorIn an unpredictable world, international life sciences collaborations can lead to misunderstandings and enforcement challenges, making an effective dispute resolution mechanism an essential risk management tool.
Latest:
Efficacy Controversy Hits European COVID-19 Vaccine RolloutDonald Macarthur and Dr. Meriem Bouslouk-Marx discuss post-approval findings of national committees in Europe charged with deciding the best strategy to use a new COVID-19 vaccine in their populations.
